Decibel Therapeutics soars on news of takeover bid

10 August 2023
decibel_therapeutics_large

US hearing loss treatment specialist Decibel Therapeutics (Nasdaq: DBTX) saw its share rocket 77% to $4.95 pre-market on Wednesday, on the news that it has agreed to be acquired by US biotech major Regeneron Pharmaceuticals (Nasdaq: REGN).

Regeneron is offering a price of $4.00 per share of Decibel common stock payable in cash at closing, with an additional non-tradeable contingent value right (CVR) to receive up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for Decibel’s lead investigational candidate, DB-OTO, within specified time periods.

The proposed acquisition puts Decibel at a total equity value of around $109 million based on the amount payable at closing, and a total equity value of up to about $213 million if the CVR milestones are achieved. The transaction is expected to close in the third quarter of 2023.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology